Filing Flows › Biodesix (BDSX) › Q3 2026
Biodesix (BDSX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Biodesix (BDSX) reported revenue of $24.0M for the third quarter 2026 (Q3 2026), +10% from a year earlier and -10% from the quarter before. Operating margin was -25.4%, net loss $8.0M (33.4% of revenue).
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $24.0M | -10% | +10% |
| Operating profit | −$6.1M | — | — |
| Net earnings | −$8.0M | — | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $24.0M in Q3 2026, up 10% year over year and down 10% from the previous quarter. Diagnostic Tests was the largest line at 96% of revenue. Diagnostic Tests added $3.2M year over year (up 16%), 142% of the total change. Development Services declined 49%.
Operating costs exceeded revenue by $6.1M, an operating margin of -25.4%. Total costs grew 5% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+13%). The quarter ended with a net loss of $8.0M, wider than the previous quarter's $7.3M loss.
Operating cash flow was −$7.2M. Non-cash charges added back $1.4M of depreciation and amortization and $852K of share-based compensation. Working capital and other items used $1.4M. Capital expenditures of $555K exceeded it, leaving free cash flow of −$7.8M.
Questions
What was Biodesix's revenue in the third quarter 2026?
Biodesix (BDSX) reported revenue of $24.0M for the third quarter 2026 (Q3 2026), +10% from a year earlier and -10% from the quarter before.
Was Biodesix profitable in the third quarter 2026?
Operating loss was $6.1M (-25.4% of revenue) and net loss $8.0M.
Source: Biodesix 10-Q on SEC EDGAR.